Results 1 to 10 of about 14,564 (189)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis [PDF]

, 2021
Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.
Meireles, Angelina, Beirão, João Nuno Melo, Pessoa, Bernardete, Figueira, João, Melo Beirão, João Nuno, Figueira, João P, Coelho, João, Monteiro, Sílvia, Coelho, Constança, Beirão, João, Malheiro, Luísa, Carneiro, Inês   +11 more
core   +1 more source

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product

Ophthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Neungseon Seo, Xiaoyan Guan, Tian Wang, Hyo S. Helen Chung, Mats Wikström, Rupa Padaki, Kevin Kalenian, Scott Kuhns, Kelli Matthies, Jill Crouse-Zeineddini, Helen Y. Wong, Michael Ng, Ian N. Foltz, Shawn Cao, Jennifer Liu   +14 more
doaj   +2 more sources

Ultrastructural features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy

Journal of Ophthalmology, 2021
Background: Proliferative diabetic retinopathy (PDR) can cause a loss of vision due to complications like vitreous hemorrhage and tractional retinal detachment, which require vitrectomy.
Vira S. Ponomarchuk, N.I. Molchaniuk, M. M. Umanets   +2 more
doaj   +1 more source

Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases

International Medical Case Reports Journal
Ikumi Kashiwagi, Ryota Nonaka, Shotaro Sasaki, Takuto Yamamoto, Kanako Yasuda, Masahiko Shimura Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, JapanCorrespondence: Masahiko Shimura, Department of ...
Kashiwagi I, Nonaka R, Sasaki S, Yamamoto T, Yasuda K, Shimura M   +5 more
doaj   +2 more sources

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. [PDF]

PLoS ONE, 2015
To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used to ...
Alberto Ferreira, Alexandros Sagkriotis, Melvin Olson, Jingsong Lu, Charles Makin, Fran Milnes   +5 more
doaj   +1 more source

Transient Vision Loss Associated with Prefilled Aflibercept Syringes

Ophthalmology Science, 2022
Purpose: To describe cases of significant vision loss after intravitreal aflibercept administration using prefilled syringes (PFS) and to study the relationships among syringe design, injection speed, and injection force.
Daniel J. Lee, MD, Brittni A. Scruggs, MD, PhD, Erik Sánchez, PhD, Merina Thomas, MD, Ambar Faridi, MD   +4 more
doaj   +1 more source

Features of aflibercept plus hyperbaric oxygen therapy for diabetic macular edema

Journal of Ophthalmology, 2022
Background: Diabetes mellitus (DM) is a disease characterized by chronic hyperglycemia and a cascade of pathological vascular alterations leading to diabetic retinopathy (DR) and diabetic macular edema (DME).
V. O. Drozdov, V. M. Sakovych
doaj   +1 more source

Comparative study between the effect of intravitreal injection of Ranibizumab and Aflibercept on macular oedema secondary to branch retinal vein occlusion [PDF]

Al-Azhar International Medical Journal, 2022
Background: Occlusion of retinal veins is a mutual disorder that affect the retina usually occurs when blood clot obstructs a retinal vein. Aim of the work: To compare the effects of Ranibizumab versus Aflibercept intravitreal injections on macular edema
Ahmed Tawfik, ahmed abdelkareem Toson, Mohamed Elmalah   +2 more
doaj   +1 more source

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience [PDF]

, 2023
Objectives:To compare the functional and anatomical outcomes of ranibizumab and aflibercept monotherapies given according to a pro re nata (PRN) protocol in treatment-naive eyes with diabetic macular edema (DME) in a real-life clinical setting.Materials ...
Süleyman Kaynak, Ferdane Ataş, Öztürk, Arif Taylan, Kaya, Mahmut, Koçak, Nilüfer, Nilüfer Koçak, Betül Akbulut Yağcı, Kaynak, Süleyman, Yağcı, Betül Akbulut, Mahmut Kaya, Ataş, Ferdane, Taylan Öztürk   +11 more
core   +1 more source

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles

Translational Oncology, 2019
Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents.
Richard A. Forsgård, Vannina G Marrachelli, Jere Lindén, Rafael Frias, Maria Carmen Collado, Riitta Korpela, Daniel Monleon, Thomas Spillmann, Pia Österlund   +8 more
doaj   +1 more source